Baxter International, a major medical products and renal care company, presents a complex investment case. The stock has suffered a dramatic decline"down 74% over five years and 35% over the past year"reflecting significant operational challenges, debt concerns from the Hill-Rom acquisition, and the recent divestiture of its kidney care segment (Vantive). The remarkably low P/E of 4.95 with EPS of $4.00 suggests either deep value or earnings that may not be sustainable in their current form post-restructuring.
Bull case: Baxter's core hospital products and medication delivery businesses serve essential healthcare needs. The aging population thesis remains intact as elderly patients disproportionately consume hospital supplies, IV solutions, and infusion therapies. At under $20, much bad news appears priced in, and recent 30/60-day momentum suggests stabilization.
Bear case: Heavy debt load, ongoing restructuring risk, and the separation from its kidney care business removes a key aging-population growth driver. The 5-year destruction of shareholder value raises governance concerns. Trading near 52-week lows with the 180-day decline of 35% signals persistent institutional selling.
Baxter offers turnaround potential but carries substantial execution risk.